贝伐珠单抗联合标准化疗方案对晚期卵巢癌患者免疫功能及生存情况的影响

Effect of Bevacizumab Combined with Standard Chemotherapy Regimen on Immune Function and Survival Situation of Patients with Advanced Ovarian Cancer

目的:观察贝伐珠单抗联合标准化疗方案对晚期卵巢癌患者免疫功能及生存情况的影响。方法:随机将2021年2月—2022年12月赣州市人民医院收治的晚期卵巢癌患者76例分为两组,各38例。对照组实施标准化疗方案(紫杉醇脂质体^(+)卡铂),在此基础上,观察组联合贝伐珠单抗治疗。比较两组临床疗效、免疫功能、肿瘤标志物、不良反应、生存情况。结果:观察组总有效率、1年生存率均高于对照组(P<0.05);治疗后,观察组人附睾蛋白4(HE4)、糖类抗原125(CA125)、CD8^(+)均较对照组低,CD3^(+)、CD4^(+)均较对照组高,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:贝伐珠单抗联合标准化疗方案可提高晚期卵巢癌临床治疗效果,降低肿瘤标志物水平,提高免疫功能,利于患者短期生存率的提升。

Objective:To observe the effect of Bevacizumab combined with standard chemotherapy regimen on immune function and survival situation of patients with advanced ovarian cancer.Method:A total of 76 patients with advanced ovarian cancer admitted to Ganzhou People's Hospital from February 2021 to December 2022 were randomly divided into two groups,with 38 cases in each group.The control group was treated with standard chemotherapy regimen(Paclitaxel Liposome+Carboplatin),on this basis,the observation group was treated with Bevacizumab.The clinical efficacy,immune function,tumor markers,adverse reactions and survival situation were compared between the two groups.Result:The total effective rate and 1-year survival rate in the observation group were higher than those of control group(P<0.05).After treatment,the levels of human epididymis protein 4(HE4),carbohydrate antigen 125(CA125)and CD8^(+) in observation group were lower than those in control group,and CD3^(+) and CD4^(+) were higher than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bevacizumab combined with standard chemotherapy regimen can improve the clinical treatment effect of advanced ovarian cancer,reduce the levels of tumor markers,improve immune function,and promote the short-term survival rate of patients.